Cargando…

Ovarian Cancer Immunotherapy and Personalized Medicine

Ovarian cancer response to immunotherapy is limited; however, the evaluation of sensitive/resistant target treatment subpopulations based on stratification by tumor biomarkers may improve the predictiveness of response to immunotherapy. These markers include tumor mutation burden, PD-L1, tumor-infil...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morand, Susan, Devanaboyina, Monika, Staats, Hannah, Stanbery, Laura, Nemunaitis, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8234871/ https://www.ncbi.nlm.nih.gov/pubmed/34207103 http://dx.doi.org/10.3390/ijms22126532

Ejemplares similares

Current Ovarian Cancer Maintenance Strategies and Promising New Developments
por: Gogineni, Vinaya, et al.
Publicado: (2021)

NF-κB Signaling in Tumor Pathways Focusing on Breast and Ovarian Cancer
por: Devanaboyina, Monika, et al.
Publicado: (2022)

BRCA1/2 Mutation Status Impact on Autophagy and Immune Response: Unheralded Target
por: Morand, Susan, et al.
Publicado: (2020)

Network based analysis identifies TP53m-BRCA1/2wt-homologous recombination proficient (HRP) population with enhanced susceptibility to Vigil immunotherapy
por: Sliheet, Elyssa, et al.
Publicado: (2021)

Rationale for the Use of Homologous Recombination Proficient Molecular Profile as a Biomarker for Therapeutic Targeting in Ovarian Cancer
por: Nemunaitis, John, et al.
Publicado: (2023)

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection: let the virus be its own demise
por: Nemunaitis, John, et al.
Publicado: (2020)

Homologous recombination proficiency in ovarian and breast cancer patients
por: Creeden, Justin Fortune, et al.
Publicado: (2021)

Pilot Study of Combination Gemogenovatucel-T (Vigil) and Durvalumab in Women With Relapsed BRCA-wt Triple-Negative Breast or Ovarian Cancer
por: Barve, Minal, et al.
Publicado: (2022)

FDA efficiency for approval process of COVID-19 therapeutics
por: Cassidy, Christine, et al.
Publicado: (2020)

Personalized immunotherapy in cancer precision medicine
por: Kiyotani, Kazuma, et al.
Publicado: (2021)

HER2-positive metastatic cervical cancer responsive to first and second-line treatment: A case report
por: Fortman, Dylan, et al.
Publicado: (2019)

Advances in Targeted Therapy for the Treatment of Cervical Cancer
por: Watkins, Dean E., et al.
Publicado: (2023)

Systemic benefit of radiation therapy via abscopal effect
por: Craig, Daniel J., et al.
Publicado: (2022)

Disparity in the era of personalized medicine for epithelial ovarian cancer
por: Devlin, Michael-John, et al.
Publicado: (2023)

Long-Term Follow-Up of Gemogenovatucel-T (Vigil) Survival and Molecular Signals of Immune Response in Recurrent Ovarian Cancer
por: Rocconi, Rodney P., et al.
Publicado: (2021)

Resident Memory T Cells and Their Effect on Cancer
por: Craig, Daniel J., et al.
Publicado: (2020)

Adenomatous polyposis coli in cancer and therapeutic implications
por: Noe, Olivia, et al.
Publicado: (2021)

Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance
por: Oh, Johnathan, et al.
Publicado: (2020)

Oral Immunotherapy (OIT): A Personalized Medicine
por: Mori, Francesca, et al.
Publicado: (2019)

The Present and Future of Allergen Immunotherapy in Personalized Medicine
por: Ridolo, Erminia, et al.
Publicado: (2022)

Immunotherapy in Ovarian Cancer
por: Siminiak, Natalia, et al.
Publicado: (2022)

Case Report: Marked Survival Advantage of Two Colorectal Cancer Patients with Liver Metastases Treated with Vigil and FOLFOX-6
por: Barve, Vedin, et al.
Publicado: (2021)

Personalized Medicine in Ovarian Cancer: A Perspective From Mexico
por: Fernandez-Garza, Luis E., et al.
Publicado: (2021)

Ovarian cancer immunotherapy: opportunities, progresses and challenges
por: Liu, Bei, et al.
Publicado: (2010)

Cancer Immunotherapy and Personalized Medicine: Emerging Technologies and Biomarker-Based Approaches
por: Maciejko, Laura, et al.
Publicado: (2017)

ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer
por: Rocconi, Rodney P., et al.
Publicado: (2022)

Adoptive immunotherapy against ovarian cancer
por: Mittica, Gloria, et al.
Publicado: (2016)

Application Of Adoptive Immunotherapy In Ovarian Cancer
por: Yang, Siyu, et al.
Publicado: (2019)

Immunotherapy Advances for Epithelial Ovarian Cancer
por: Hartnett, Erin G., et al.
Publicado: (2020)

Author Correction: ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer
por: Rocconi, Rodney P., et al.
Publicado: (2023)

Novel Biomarkers for Personalized Cancer Immunotherapy
por: Shindo, Yoshitaro, et al.
Publicado: (2019)

Benefits of functional assays in personalized cancer medicine: more than just a proof-of-concept
por: Bounaix Morand du Puch, Christophe, et al.
Publicado: (2021)

Ovarian Cancer Immunotherapy: Turning up the Heat
por: Ghisoni, Eleonora, et al.
Publicado: (2019)

Pilot Trial of FANG Immunotherapy in Ewing's Sarcoma
por: Ghisoli, Maurizio, et al.
Publicado: (2015)

Deregulated miRNA clusters in ovarian cancer: Imperative implications in personalized medicine
por: Kandettu, Amoolya, et al.
Publicado: (2022)

Biomarkers of Response and Resistance to Immunotherapy in Microsatellite Stable Colorectal Cancer: Toward a New Personalized Medicine
por: Huyghe, Nicolas, et al.
Publicado: (2022)

Immunotherapies in ovarian cancer
por: García-Martínez, Elena, et al.
Publicado: (2020)

Epigenome-Driven Strategies for Personalized Cancer Immunotherapy
por: Rocha, Gabriel Iudy Yamaguchi, et al.
Publicado: (2023)

Immunotherapy of Ovarian Cancer: The Role of Checkpoint Inhibitors
por: De Felice, Francesca, et al.
Publicado: (2015)

Immune checkpoints, their control by immunotherapy and ovarian cancer
por: Bose, Chinmoy K.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_l1v5b2lim65tagu1diock3od8p